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Objectives: To investigate whether the wax moth larva, Galleria mellonella, is a suitable host for assessing the
in vivo efficacy of antistaphylococcal agents against Staphylococcus aureus and methicillin-resistant S. aureus
(MRSA) infections.
Methods: Wax moth larvae were infected with increasing doses of S. aureus to investigate the effect of inocu-
lum size on larval survival. In addition, infected wax moth larvae were treated with daptomycin, penicillin or
vancomycin to examine whether these agents were effective against S. aureus and MRSA infections in vivo.
Results: Increasing inoculum doses of live S. aureus cells resulted in greater larval mortality, but heat-killed bac-
teria and cell-free culture filtrates had no detrimental effects on survival. Larval mortality rate also depended
on the post-inoculation incubation temperature. After larvae were infected with S. aureus, larval survival was
enhanced by administering the antistaphylococcal antibiotics daptomycin or vancomycin. Larval survival
increased with increasing doses of the antibiotics. Moreover, penicillin improved survival of larvae infected
with a penicillin-susceptible methicillin-susceptible S. aureus (MSSA) strain, but it was ineffective at similar
doses in larvae infected with MRSA (penicillin resistant). Daptomycin and vancomycin were also effective
when administered to the larvae prior to infection with bacteria.
Conclusions: This is the first report to demonstrate that antibiotics are effective in the wax moth larva model
for the treatment of infections caused by Gram-positive bacteria. The new wax moth larva model is a useful
preliminary model for assessing the in vivo efficacy of candidate antistaphylococcal agents before proceeding
to mammalian studies, which may reduce animal experimentation and expense.
Keywords: antibacterial, antimicrobial, daptomycin, drug discovery, drug resistance, insect infection model, MRSA,
Staphylococcus aureus, vancomycin
Introduction
Staphylococcus aureus is a major cause of community and noso-
comial infections. Strains with resistance to antibiotics, including
methicillin-resistant S. aureus (MRSA), are particularly proble-
matic, as infections caused by these microbes are difficult and
expensive to treat.1,2 As resistance to conventional and newly
introduced agents is commonly encountered3,4 new treatment
options are under active investigation.5–8 After identifying an
antibacterial compound with potent antistaphylococcal activity
in vitro, evaluations are performed to determine its efficacy in
complex biological fluids (human serum for instance) and tox-
icity. Compounds deemed to be non-toxic but effective in sera
must then be assessed for efficacy in vivo. Typically a mamma-
lian system is used (e.g. a murine infection model), but these
experiments are time-consuming, expensive and require full
ethical consideration. Moreover, many compounds prove to be
ineffective in vivo for various reasons, including binding to
immune components or enzymatic degradation. Hence there is
a need for preliminary and alternative infection models that gen-
erate in vivo data quickly and inexpensively and that do not
require the same ethical considerations. Such new models can
reduce animal experimentation by highlighting compounds
that are unlikely to be effective in mammalian systems.
The introduction of a wax moth model of systemic S. aureus
infection may prove useful to this end. Like other non-
mammalian infection models,9–12 microbial virulence is similar
in the wax moth larva and mammals, and this model has
already been used to determine the virulence of various
human pathogens, including S. aureus.13–20 S. aureus mutants
lacking the accessory gene regulator (agr) gene, which controls
the global expression of multiple virulence factors, have attenu-
ated virulence in mammalian models and these strains are simi-
larly less virulent in the wax moth larva.16 This model has also
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been used to identify novel virulence genes in
S. aureus. For example, strains with point mutations in relA that
result in a permanently activated stringent response are less
virulent in the wax moth larva.19 Further, Purves et al.20 demon-
strated that two glyceraldehyde-3-phosphate dehydrogenase
homologues have reduced virulence in this model. The benefits
of the wax moth larva model compared with some other non-
mammalian models of infection are numerous. First, the insect
immune response is similar to the innate immune response of
mammals and pathogen killing occurs by similar mechan-
isms.10,21 Second, the wax moth model can be run at the
human core body temperature of 378C, which can be important
for the expression of certain microbial virulence factors.22 Third,
an accurate inoculum of the pathogen can be delivered directly
into the host’s body. Finally, and crucially, the wax moth model
is also amenable for assessing the efficacy of antimicrobial
agents, and this model has been used to study therapeutics
for infections, including those caused by Acinetobacter bauman-
nii and fungi.17,23–25
The aim of this study was to determine the usefulness of the
wax moth larva model of systemic S. aureus infection for evalu-
ating the efficacy of antistaphylococcal agents.
Materials and methods
Reagents, microorganisms and insects
All reagents and culture media were purchased from Sigma–Aldrich Ltd
(Poole, UK) except daptomycin (Novartis Pharmaceuticals, Horsham, UK),
penicillin G (Duchefa Biochemie, Ipswich, UK) and vancomycin (Duchefa
Biochemie B.V., Haarlem, The Netherlands). All solutions were made
with sterile ultrapure deionized water (Maxima; Elga, High Wycombe,
UK). Water, PBS (for 1 L: 8 g of NaCl, 0.2 g of KCl, 1.15 g of Na2HPO4
and 0.2 g of KH2PO4; pH 7.3) and media were sterilized by autoclaving
at 1218C for 15 min. S. aureus Newman (methicillin-susceptible; MSSA)
and S. aureus BB270 (MRSA) were sourced and cultured for inoculum
preparation as described previously.7 MICs of daptomycin, penicillin and
vancomycin were determined for each S. aureus strain according to the
CLSI protocol.26 For daptomycin MICs, Mueller–Hinton broth was sup-
plemented with CaCl2 to 50 mg/L. Batches of wax moth larvae (75 g;
Livefood UK Ltd, Rooks Bridge, UK) in their final instar stage were
stored in the dark at 48C and used within 7 days of receipt. Larval
masses varied slightly but were typically 250 mg, and this value was
used to calculate treatment doses. Unless stated, all experimentation
used groups containing 15 larvae and each experiment was repeated
using larvae from a different batch. In all experiments there were two
negative control groups; one group that underwent no manipulation
whatsoever, while the other group (uninfected control) was injected
with PBS only, which controlled for the impact of physical trauma. Typi-
cally there were no deaths in these control groups and there were
never more than two deaths per control group per experiment. During
the following experimentation, larvae were stored in Petri dishes in the
dark at 378C for 120 h. Larvae were inspected every 24 h and were con-
sidered dead if they did not move in response to touch.
Inoculation of larvae with culture filtrate, heat-killed
or live S. aureus
S. aureus Newman cells were harvested in mid- to late-exponential phase
by centrifugation at 2500 g for 10 min. To examine the effect of culture
filtrates on larval survival, the supernatant was passed through a sterile
polyethersulfone 0.22 mm filter (Millipore, Watford, Herts, UK). Meanwhile,
the cell pellet was washed by re-suspension in PBS and then centrifu-
gation was performed as before. This wash was repeated before cell
density of the resultant bacterial suspension was determined by measur-
ing optical density at 570 nm (OD570). The bacterial suspension was
diluted with PBS to give the desired cfu/mL. Larvae were inoculated
with 10 mL of bacterial suspension (containing 1×105–1×107 cfu total)
in the last left proleg using a 50 mL Hamilton syringe. For heat-killed
inoculum experiments, the bacterial suspension was kept in a water
bath at 908C for 30 min. Heat killing was confirmed by plating 100 mL
of bacterial suspension across tryptone soya agar (TSA) and incubating
this plate at 378C for 48 h. The heat-killed bacterial suspension was
diluted with PBS and inocula equivalent to 1×106–5×107 cfu were
used for infecting the larvae, as above.
Effect of post-inoculation temperature on larval survival
To investigate the effect of post-inoculation incubation temperature on
the survival of infected larvae, larvae were inoculated with 2.5×106 cfu
of live bacteria and incubated at 25, 30 or 378C. Negative control
groups were set-up for each incubation temperature.
Toxicity of antistaphylococcal agents to larvae
The toxicities of the antistaphylococcal agents (daptomycin, penicillin and
vancomycin) were tested by administering repeat doses of 64 mg/kg at
0, 24 and 48 h to groups of 10 larvae. This treatment dose was in excess
of those used in subsequent experimentation (see below). Treatments
were administered similar to the initial inoculation, but these were given
into alternate prolegs moving up the body toward the head such that
each proleg was injected only once.23 A non-significant difference in
larval survival between the treated group and the control group (injected
with PBS only) would indicate a lack of toxicity up to the dose and
regimen under examination.
Treatment of infected larvae with antistaphylococcal
agents
Groups of larvaewere inoculatedwith live S. aureus (2.5×106 cfu; Newman
or BB270) as above. All larvae were confirmed to be alive at 2 h
post-inoculation (here designated 0 h). Then, the first treatment doses of
daptomycin (2, 10 and 50 mg/kg), penicillin (0.5, 2 and 5 mg/kg) or
vancomycin (1, 10 and 50 mg/kg) were administered in PBS. In addition,
one group of larvae that had been inoculated with live bacteria received
PBS only as treatment. Repeat treatment doses of daptomycin,
penicillin, vancomycin or PBS were given at 24 and 48 h. In addition, the
uninfected control group received PBS treatments to control for multiple
injections.
Pre-treatment of larvae with antistaphylococcal agents
To assess the ability of daptomycin and vancomycin to protect against
subsequent S. aureus Newman infection, single treatment doses of dap-
tomycin (2, 10 and 50 mg/kg) and vancomycin (1, 10 and 50 mg/kg)
were given 2 h prior to inoculation with live bacteria (2.5×106 cfu), as
described above. For this experiment the time of inoculation was desig-
nated 0 h.
Statistical analyses
Statistical tests were performed using SPSS v17.0 for Windows (SPSS Inc.,
Chicago, IL, USA). For statistical testing and the preparation of figures,
data from duplicate experiments were pooled to give n¼30, except the
toxicity determinations, which were performed once only and used a
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group size of 10. These pooled survival data were plotted using the
Kaplan–Meier method and comparisons made between groups using
the log rank test. In all cases P≤0.05 was considered significant and
Holm’s correction27 was applied to account for multiple comparisons.
In all comparisons to the negative control it was the uninfected control
(rather than the ‘no manipulation’ control) that was used.
Results
Effect of inoculum dose on larval survival
The heat-killed S. aureus Newman inoculum (up to the maximum
inoculation dose of 5×107 cfu) and cell-free culture filtrate had
no significant effect on larval survival (P.0.05; Figure 1 and
data not shown). With the live bacterial inocula, larval survival
was affected by the inoculum dose and larger doses of bacteria
gave reduced larval survival in a dose-dependent manner during
120 h incubation (Figure 1). Even the lowest inoculum
(1×105 cfu) reduced larval survival compared with the
uninfected control, though this just failed to achieve statistical
significance (P¼0.078) (Figure 1). Further, post-inoculation
temperature affected larval survival after injection of live
S. aureus Newman (Figure 1). During 120 h of incubation, larval
survival was lowest in the group kept at 378C, while percentage
survival was significantly greater (P,0.05) for the groups kept
at 25 and 308C (Figure 1).
Treatment of S. aureus-infected larvae with daptomycin,
penicillin or vancomycin
Daptomycin, penicillin or vancomycin at 64 mg/kg had no effect
on larval survival compared with the PBS-treated controls
(P.0.05) and were therefore deemed to be non-toxic at these
doses (data not shown). Treatment of larvae that had been
infected with 2.5×106 cfu S. aureus Newman showed that the
percentage larval survival increased with increasing concen-
trations of daptomycin and vancomycin in a dose-dependent
manner (Figure 2). However, only those groups that received
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Figure 1. (a) Effect of varying inoculum dose of live S. aureus Newman on the survival of G. mellonella larvae during incubation at 378C showing that
survival is reduced with increasing doses of bacteria in a dose-dependent manner. Data from the greatest dose of heat-killed (h.k.) bacterial inoculum
is also given showing that heat-killed S. aureus had no significant effect on larval survival. (b) Effect of post-inoculation temperature on the survival of
G. mellonella larvae after infection with 2.5×106 cfu of live S. aureus Newman showing that survival is reduced with increasing post-inoculation
temperature. There were no deaths in each of the uninfected control groups (incubated at 25, 30 and 378C; n¼30).
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Figure 2. Effect of treatment of G. mellonella larvae (inoculated with 2.5×106 cfu of S. aureus Newman; n¼30) with (a) daptomycin (2, 10 and
50 mg/kg) and (b) vancomycin (1, 10 and 50 mg/kg) on survival at 378C. First treatments were administered at 0 h (i.e. 2 h after inoculation),
with subsequent treatments at 24 and 48 h. These data indicate that antistaphylococcal agents are efficacious against an MSSA strain in the
wax moth larvae in a dose-dependent manner.
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≥10 mg/kg of either of these antibiotics had a significantly
greater percentage survival compared with the larvae treated
with PBS only (P,0.05). Similarly, for those groups of larvae
infected with S. aureus BB270, the percentage larval survival
increased with increasing concentrations of daptomycin and
vancomycin but, again, ≥10 mg/kg of either antibiotic was
needed for a significant increase in percentage survival com-
pared with the larvae treated with PBS only (P,0.05)
(Figure 3). The MICs for S. aureus Newman were 2 mg/L for dap-
tomycin and vancomycin, while S. aureus BB270 MICs were 4 and
2 mg/L for these agents, respectively.
The use of penicillin (0.5–5 mg/kg) in larvae infected with
S. aureus Newman (MSSA) showed that survival was significantly
greater at each of these doses compared with those larvae
treated with PBS only (P,0.05) (Figure 4). In contrast, these
penicillin treatment regimens had no beneficial effects for
larvae infected with the MRSA strain, S. aureus BB270 (P.0.05
in each case) (Figure 4). The MICs of penicillin for S. aureus
Newman and S. aureus BB270 were 0.031 and 64 mg/L,
respectively.
Pre-treatment of larvae with daptomycin and
vancomycin
Single treatment doses of daptomycin and vancomycin adminis-
tered before inoculation with S. aureus Newman improved larval
survival (Figure 5). This protective effect was dose-dependent,
with greater doses of these agents increasing larval survival,
though improvements in survival were only significant
(P,0.05) for those groups receiving ≥10 mg/kg of either
antibiotic.
Discussion
Daptomycin and vancomycin are capable of improving the survi-
val of wax moth larvae in a dose-dependent manner after
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Figure 3. Effect of treatment of G. mellonella larvae (inoculated with 2.5×106 cfu of S. aureus BB270; n¼30) with (a) daptomycin (2, 10 and
50 mg/kg) or (b) vancomycin (1, 10 and 50 mg/kg) on survival at 378C. First treatments were administered at 0 h (i.e. 2 h after inoculation),
with subsequent treatments at 24 and 48 h. These data indicate that antistaphylococcal agents are efficacious against an MRSA strain in the
wax moth larvae in a dose-dependent manner.
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Figure 4. Effect of treatment of G. mellonella larvae (n¼30 for each drug and dose combination) inoculated with 2.5×106 cfu of (a) S. aureus
Newman or (b) S. aureus BB270 with penicillin (0.5, 2 and 5 mg/kg) on survival at 378C. First treatments were administered at 0 h (i.e. 2 h after
inoculation), with subsequent treatments at 24 and 48 h. These data confirm that penicillin is effective against the Newman strain (MSSA) but has
no effect against the BB270 strain (MRSA).
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systemic S. aureus infection. These agents are similarly effective
when administered to the larvae prior to S. aureus inoculation.
Penicillin treatment improves the survival of larvae infected
with MSSA but has no beneficial effect for those larvae infected
with MRSA. Lethality of S. aureus infection is dependent on the
dose of live bacteria given and the incubation temperature
after inoculation.
Previously the wax moth model has been used to evaluate
the efficacy of antimicrobial agents,17,23–25 but the present
study is the first to show that clinically approved antibiotics are
effective in this model against infections caused by Gram-
positive bacteria, specifically S. aureus and MRSA. Interestingly,
daptomycin and vancomycin are efficacious in the wax moth
model at doses similar to those recommended for use in
humans with S. aureus or MRSA infections, notably 4–6 and
10–20 mg/kg/day of these drugs, respectively.28 Moreover,
both daptomycin and vancomycin enhance larval survival
when administered as prophylaxis before infection with bacteria.
The beneficial effect of a single prophylactic dose provides similar
increases in larval survival compared with three doses adminis-
tered post-infection. While penicillin improves the survival of
larvae infected with the Newman strain (MSSA), it is ineffective
in larvae infected with BB270, an MRSA strain. These in vivo
observations reflect the known differences in susceptibility of
these two strains to the action of penicillin in vitro. Though peni-
cillin G is not recommended for S. aureus infections, its dose for
other diseases in humans is 30–60 mg/kg/day, which is not
dissimilar from its effective dose in the wax moth larva against
the penicillin-susceptible Newman strain. Taken together, these
findings confirm that the wax moth model may prove useful
for evaluating the in vivo efficacy of new antistaphylococcal
agents.
Peleg et al.16 were the first to demonstrate that the wax
moth larva model of S. aureus infection could prove to be
useful for identifying pathogenicity and virulence genes. Our
study confirms that live bacteria are needed to kill wax
moth larvae, as neither culture filtrate nor heat-killed cells
causes significant mortality (even at .500 times the dose of
live bacteria that is needed for significant effects on survival).
Thus Galleria mellonella larvae seem to be actively and
specifically killed by S. aureus. We also confirm a previous
observation that higher post-inoculation temperatures cause
greater reductions in larval survival.16 Some bacteria have
thermo-regulated virulence factors, which could account for
this observation, and there is some evidence for the existence
of such genes in S. aureus.29 However, it is perhaps more likely
that the bacterium grows, divides and/or produces virulence
factors faster at 378C compared with 30 or 258C, thereby
killing the larva more quickly.
While the precise mechanisms for wax moth larva killing by
S. aureus remain enigmatic, it is important to identify the key
virulence factors most relevant in this model. In addition,
studies are also needed to elucidate the dynamics for
S. aureus infection of the wax moth larva. Even low doses of
live bacteria (1×105 cfu) cause significant reductions in larval
survival, but it is not clear whether the bacterium is dividing
in the host during infection or merely remaining static and
producing the necessary virulence factors to cause death. If
S. aureus does divide in the wax moth larva in vivo it would
be desirable to establish whether a threshold exists that
causes a lethal event. The assessment of bacterial burden in
larval haemolymph19 may also prove useful for increasing
the assay’s sensitivity, and these values could be compared
with blood and tissue burden that are often measured
during murine infection models. Finally, the existence of drug-
binding immune components and drug degradation pathways
warrants investigation in this model.
In conclusion, the new wax moth larva model is a useful pre-
liminary model for assessing the in vivo efficacy of candidate
anti-S. aureus and anti-MRSA agents before proceeding to mam-
malian studies, which may reduce animal experimentation and
costs.
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